

Adnan Kastrati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9260358/publications.pdf>

Version: 2024-02-01

681
papers

91,212
citations

529

127
h-index

336

286
g-index

704
all docs

704
docs citations

704
times ranked

43832
citing authors

#	ARTICLE	IF	CITATIONS
1	Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial. <i>Clinical Research in Cardiology</i> , 2023, 112, 518-528.	3.3	2
2	Design and Rationale of a Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy (COBRA-REDUCE). <i>Cardiovascular Revascularization Medicine</i> , 2022, 34, 17-24.	0.8	9
3	Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease. <i>Annals of Thoracic Surgery</i> , 2022, 113, 554-562.	1.3	5
4	Long-term clinical outcomes after drug eluting stent implantation with and without stent overlap. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 541-551.	1.7	5
5	Prediction of risk for bleeding, myocardial infarction and mortality after percutaneous coronary intervention in patients with acute coronary syndromes. <i>Coronary Artery Disease</i> , 2022, Publish Ahead of Print, .	0.7	2
6	Prognostic impact of secondary prevention after coronary artery bypass grafting—insights from the TiCAB trial. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 62, .	1.4	4
7	Preadmission antiplatelet therapy and treatment effect of ticagrelor versus prasugrel in patients with acute coronary syndromes - a subgroup analysis of the ISAR-REACT 5 trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, , .	3.0	1
8	Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial. <i>EuroIntervention</i> , 2022, 17, 1348-1351.	3.2	3
9	Antiplatelet therapy after percutaneous coronary intervention. <i>EuroIntervention</i> , 2022, 17, e1371-e1396.	3.2	94
10	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, , .	0.6	5
11	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120009495.	3.9	4
12	Stent Optimization Using Optical Coherence Tomography and Its Prognostic Implications After Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2022, 11, e023493.	3.7	5
13	Harnessing feature extraction capacities from a pre-trained convolutional neural network (VGG-16) for the unsupervised distinction of aortic outflow velocity profiles in patients with severe aortic stenosis. <i>European Heart Journal Digital Health</i> , 2022, 3, 153-168.	1.7	6
14	Rotational atherectomy of calcified coronary lesions: current practice and insights from two randomized trials. <i>Clinical Research in Cardiology</i> , 2022, , .	3.3	5
15	Periprocedural myocardial injury according to optical characteristics of neointima and treatment modality of in-stent restenosis. <i>Clinical Research in Cardiology</i> , 2022, 111, 827-837.	3.3	2
16	Management of in-stent restenosis. <i>EuroIntervention</i> , 2022, 18, e103-e123.	3.2	34
17	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 829-844.	13.7	30
18	Clinical outcomes of complete versus incomplete revascularization in patients treated with coronary artery bypass grafting: insights from the TiCAB trial. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 59, 417-425.	1.4	6

#	ARTICLE	IF	CITATIONS
19	Anatomic and Flow Characteristics of Left Anterior Descending Coronary Artery Angiographic Stenoses Predisposing to Myocardial Infarction. American Journal of Cardiology, 2021, 141, 7-15.	1.6	1
20	Evaluation of a Low-Dose Radiation Protocol During Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2021, 139, 71-78.	1.6	2
21	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	2.2	3,048
22	Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTEMI-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1368-1378.	2.2	33
23	Questions and answers on workup diagnosis and risk stratification: a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1379-1386.	2.2	11
24	The Bayesian Approach and the Results of the ISAR-REACT 5 Trial. JACC: Cardiovascular Interventions, 2021, 14, 231-232.	2.9	0
25	Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2021, 10, e018304.	3.7	9
26	Letter by Kessler et al Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52,816 Patients From 12 Randomized Trials". Circulation, 2021, 143, e230-e231.	1.6	0
27	Antithrombotic treatment in primary percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2021, 19, 313-324.	1.5	2
28	Guided P2Y12 inhibitor therapy after percutaneous coronary intervention. Lancet, The, 2021, 397, 1423-1425.	13.7	8
29	A proteomic atlas of the neointima identifies novel druggable targets for preventive therapy. European Heart Journal, 2021, 42, 1773-1785.	2.2	11
30	Stent Thrombosis in Patients Treated for Acute or Chronic Coronary Syndrome. JACC: Cardiovascular Interventions, 2021, 14, 1091-1093.	2.9	0
31	Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention. JAMA Cardiology, 2021, 6, 1121.	6.1	11
32	Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e020165.	3.7	5
33	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2021, 14, e010565.	3.9	4
34	Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease. JAMA Cardiology, 2021, 6, 753.	6.1	44
35	Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention. Future Cardiology, 2021, 17, 539-547.	1.2	0
36	Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis. EuroIntervention, 2021, 17, e388-e395.	3.2	16

#	ARTICLE	IF	CITATIONS
37	Clinical burden and implications of coronary interventions for in-stent restenosis. <i>EuroIntervention</i> , 2021, 17, e355-e357.	3.2	8
38	Primary PCI, Late Presenting STEMI, and the Limits of Time. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1306-1308.	2.8	5
39	Efficacy and safety of ticagrelor versus prasugrel in smokers and nonsmokers with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2021, 338, 8-13.	1.7	1
40	Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1117-1124.	1.0	5
41	Subphenotyping of Patients With Aortic Stenosis by Unsupervised Agglomerative Clustering of Echocardiographic and Hemodynamic Data. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2127-2140.	2.9	21
42	Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2021, 10, e021418.	3.7	1
43	Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, , .	0.6	0
44	Optical Coherence Tomography Tissue Coverage and Characterization with Grey-Scale Signal Intensity Analysis After Bifurcation Stenting with a New Generation Bioabsorbable Polymer Drug-Eluting Stent. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 277-285.	0.8	0
45	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). <i>European Heart Journal</i> , 2020, 41, 3715-3728.	2.2	121
46	Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease—A meta-analysis of randomized clinical trials. <i>American Heart Journal</i> , 2020, 219, 109-116.	2.7	6
47	Relation of Hypcholesterolemia With Diabetes Mellitus in Patients With Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2020, 125, 1026-1032.	1.6	1
48	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. <i>Thrombosis and Haemostasis</i> , 2020, 120, 348-362.	3.4	13
49	Efficacy of drug-coated balloon angioplasty in early versus late occurring drug-eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1008-1015.	1.7	4
50	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020, 41, 3533-3545.	2.2	93
51	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2238-2247.	2.9	27
52	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2020, 173, 436-444.	3.9	44
53	Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2266-2274.	2.9	13
54	Ticagrelor or Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 2329-2337.	1.6	26

#	ARTICLE	IF	CITATIONS
55	Angiographic performance of everolimus-eluting stents for the treatment of coronary in-stent restenosis in daily practice. Catheterization and Cardiovascular Interventions, 2020, 98, 857-862.	1.7	1
56	Reply. Journal of the American College of Cardiology, 2020, 76, 1392-1393.	2.8	0
57	In-Stent Restenosis in the United States. Journal of the American College of Cardiology, 2020, 76, 1532-1535.	2.8	8
58	Outcomes after complete dissolution of everolimus-eluting bioresorbable scaffolds implanted during routine practice. Revista Espanola De Cardiologia (English Ed), 2020, 74, 584-590.	0.6	0
59	SARS-CoV-2 Infection in Asymptomatic Patients Hospitalized for Cardiac Emergencies: Implications for Patient Management. Frontiers in Cardiovascular Medicine, 2020, 7, 599299.	2.4	1
60	Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, 2020, 76, 2436-2446.	2.8	41
61	Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients. Journal of the American College of Cardiology, 2020, 76, 2569-2571.	2.8	28
62	Hybrid PET/MR imaging for the prediction of left ventricular recovery after percutaneous revascularisation of coronary chronic total occlusions. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3074-3083.	6.4	9
63	Randomized Comparison of Intensified and Standard P2Y ₁₂ -Receptor-Inhibition Before Elective Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008649.	3.9	29
64	Long-Term Ticagrelor Versus Prasugrel Pharmacodynamics in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e015726.	3.7	3
65	10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents. Journal of the American College of Cardiology, 2020, 76, 146-158.	2.8	49
66	Hospital admissions with acute coronary syndromes during the COVID-19 pandemic in German cardiac care units. Cardiovascular Research, 2020, 116, 1800-1801.	3.8	10
67	Mechanistic insights into the superior clinical efficacy of prasugrel over ticagrelor. European Heart Journal, 2020, 41, 3153-3155.	2.2	1
68	Predicting factors for long-term survival in patients with out-of-hospital cardiac arrest â€” A propensity score-matched analysis. PLoS ONE, 2020, 15, e0218634.	2.5	7
69	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. Journal of the American College of Cardiology, 2020, 75, 2664-2678.	2.8	93
70	Sex differences in the outcome after percutaneous coronary intervention â€” A propensity matching analysis. Cardiovascular Revascularization Medicine, 2019, 20, 101-107.	0.8	17
71	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	2.2	2,687
72	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	2.2	4,537

#	ARTICLE	IF	CITATIONS
73	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	1.4	402
74	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). European Heart Journal, 2019, 40, 2070-2085.	2.2	64
75	Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. European Heart Journal, 2019, 40, 2432-2440.	2.2	61
76	Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI—Design and Rationale of the Randomized ISAR-PLASTER Trial. Thrombosis and Haemostasis, 2019, 119, 1539-1545.	3.4	26
77	Inverse association of alanine aminotransferase within normal range with prognosis in patients with coronary artery disease. Clinica Chimica Acta, 2019, 496, 55-61.	1.1	15
78	Progress in Drug-Eluting Stent Technology. JACC: Cardiovascular Interventions, 2019, 12, 1661-1664.	2.9	4
79	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2019, 381, 1524-1534.	27.0	543
80	Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials. European Journal of Cardio-thoracic Surgery, 2019, 57, 520-528.	1.4	3
81	Subintimal Versus Intraplaque Recanalization of Coronary Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2019, 12, 1889-1898.	2.9	14
82	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	27.0	683
83	U-shaped association of central pulse pressure with long-term prognosis after ST-segment elevation myocardial infarction. Heart and Vessels, 2019, 34, 1104-1112.	1.2	3
84	Relationship of left ventricular end-diastolic pressure with extent of myocardial ischemia, myocardial salvage and long-term outcome in patients with ST-segment elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2019, 93, 901-909.	1.7	8
85	Genetically modulated educational attainment and coronary disease risk. European Heart Journal, 2019, 40, 2413-2420.	2.2	32
86	Monocyte-platelet aggregates affect local inflammation in patients with acute myocardial infarction. International Journal of Cardiology, 2019, 287, 7-12.	1.7	15
87	Qualitative and quantitative neointimal characterization by optical coherence tomography in patients presenting with in-stent restenosis. Clinical Research in Cardiology, 2019, 108, 1059-1068.	3.3	13
88	Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. Cardiovascular Research, 2019, 115, 1512-1518.	3.8	15
89	One-year clinical outcome with a novel self-expanding transcatheter heart valve. Catheterization and Cardiovascular Interventions, 2019, 94, 783-792.	1.7	11
90	Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial. European Journal of Cardio-thoracic Surgery, 2019, 57, 732-739.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease. <i>Circulation</i> , 2019, 139, 325-333.	1.6	97
92	Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis. <i>International Journal of Cardiology</i> , 2019, 276, 212-217.	1.7	9
93	Outcome after new generation single-layer polytetrafluoroethylene-covered stent implantation for the treatment of coronary artery perforation. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 912-920.	1.7	22
94	Relation of Ratio of Left Ventricular Ejection Fraction to Left Ventricular End-Diastolic Pressure to Long-Term Prognosis After ST-Segment Elevation Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2019, 123, 199-205.	1.6	9
95	Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial. <i>European Heart Journal</i> , 2019, 40, 167-176.	2.2	40
96	High-sensitivity cardiac troponin T in patients with ST-segment elevation myocardial infarction. <i>Journal of Cardiology</i> , 2019, 73, 333-334.	1.9	0
97	Genetic testing to guide therapy? Not for ticagrelor!. <i>European Heart Journal</i> , 2019, 40, e1-e3.	2.2	6
98	Sex and long-term outcomes after implantation of the Absorb bioresorbable vascular scaffold for treatment of coronary artery disease. <i>EuroIntervention</i> , 2019, 15, 615-622.	3.2	7
99	Incidence and predictors of stent thrombosis after endovascular revascularisation of the superficial femoral artery. <i>EuroIntervention</i> , 2019, 15, e1107-e1114.	3.2	13
100	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>EuroIntervention</i> , 2019, 14, 1435-1534.	3.2	367
101	Incidental findings in multislice computed tomography prior to transcatheter aortic valve implantation: frequency, clinical relevance and outcome. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 985-992.	1.5	8
102	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. <i>International Journal of Cardiology</i> , 2018, 263, 24-28.	1.7	6
103	Rebuttal: Comparative prognostic value of postprocedural creatine kinase myocardial band and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 635-636.	1.7	4
104	Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials. <i>Clinical Research in Cardiology</i> , 2018, 107, 788-798.	3.3	11
105	What Treatment Should We Dare in Patients With In-Stent Restenosis?. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 284-286.	2.9	4
106	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 68-76.	2.9	28
107	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 53-65.	2.9	22
108	Incidencia y predictores de la reestenosis recurrente tras angioplastia con balón farmacoactivo en reestenosis de stents farmacoactivos: proyecto cooperativo ICARUS. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 620-627.	1.2	14

#	ARTICLE	IF	CITATIONS
109	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>European Heart Journal</i> , 2018, 39, e1-e33.	2.2	22
110	Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2018, 71, 42.	0.6	29
111	Vascular response to percutaneous coronary intervention with biodegradable-polymer vs. new-generation durable-polymer drug-eluting stents: a meta-analysis of optical coherence tomography imaging trials. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 1294-1301.	1.2	9
112	Efficacy Over Time With Drug-Eluting Stents in Saphenous Vein Graft Lesions. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1973-1982.	2.8	52
113	High-sensitivity cardiac troponin T and prognosis in patients with ST-segment elevation myocardial infarction. <i>Journal of Cardiology</i> , 2018, 72, 220-226.	1.9	15
114	Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. <i>International Journal of Cardiology</i> , 2018, 258, 42-49.	1.7	12
115	Comparative prognostic value of postprocedural creatine kinase myocardial band and high-sensitivity troponin T in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 215-223.	1.7	16
116	Endovascular Treatment for Steno-Occlusive Iliac Artery Disease: Safety and Long-Term Outcome. <i>Angiology</i> , 2018, 69, 308-315.	1.8	8
117	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2018, 39, 119-177.	2.2	7,100
118	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	2.2	2,246
119	Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. <i>European Heart Journal</i> , 2018, 39, 1591-1601.	2.2	45
120	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 34-78.	1.4	261
121	Incidence and predictors of reCurrent restenosis after drug-coated balloon Angioplasty for Restenosis of a drug-eluting Stent: The ICARUS Cooperation. <i>Revista Espanola De Cardiologia (English) Tj ETQq1 1 0.784314rgBT /Ov</i>	0.7	43
122	Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2018, 121, 461-468.	1.6	12
123	Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. <i>Clinica Chimica Acta</i> , 2018, 476, 130-138.	1.1	109
124	Postprocedural high-sensitivity troponin T and prognosis in patients with non-ST-segment elevation myocardial infarction treated with early percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 480-486.	0.8	5
125	Emergency extracorporeal membrane oxygenation in transcatheter aortic valve implantation: A two-center experience of incidence, outcome and temporal trends from 2010 to 2015. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 149-156.	1.7	22
126	Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006752.	3.9	32

#	ARTICLE	IF	CITATIONS
127	Strengths and Limitations of Real World Data in Patients Treated With Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007239.	3.9	4
128	Comparison of Vascular Closure Devices Versus Manual Compression After Femoral Artery Puncture in Women. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006074.	3.9	12
129	High-Speed Rotational Atherectomy Versus Modified Balloons Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007415.	3.9	164
130	Patent foramen ovale closure for patients excluded from the randomized cryptogenic stroke trials: response to letter by Zaman et al.. <i>Clinical Research in Cardiology</i> , 2018, 107, 1189-1191.	3.3	0
131	Creatine kinase myocardial band - a biomarker to assess prognostically relevant periprocedural myocardial infarction. <i>International Journal of Cardiology</i> , 2018, 270, 118-119.	1.7	9
132	Percutaneous coronary intervention: balloons, stents and scaffolds. <i>Clinical Research in Cardiology</i> , 2018, 107, 55-63.	3.3	11
133	Neoatherosclerosis in Patients With Coronary Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1340-1350.	2.9	35
134	Multi-ethnic genome-wide association study for atrial fibrillation. <i>Nature Genetics</i> , 2018, 50, 1225-1233.	21.4	552
135	Ultrasound-guided thrombin injection for treatment of femoral artery pseudoaneurysm with concomitant AV-fistula "a retrospective single centre experience. <i>Vasa - European Journal of Vascular Medicine</i> , 2018, 47, 507-512.	1.4	3
136	Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2018, 13, 1565-1573.	3.2	35
137	Outcomes of patients treated with ultrathin-strut biodegradable polymer sirolimus-eluting stents versus fluoropolymer-based everolimus-eluting stents: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2018, 14, 224-231.	3.2	16
138	Implantation of a MitraClip between two previously implanted MitraClips to treat recurrent severe mitral regurgitation. <i>Journal of Cardiology Cases</i> , 2017, 15, 50-52.	0.5	3
139	Long-Term Outcomes After MitraClip Implantation According to the Presence or Absence of EVEREST Inclusion Criteria. <i>American Journal of Cardiology</i> , 2017, 119, 1255-1261.	1.6	57
140	Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 477-485.	2.9	12
141	Reperfusion injury in ST-segment elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2017, 28, 253-262.	0.7	17
142	Randomized Comparison of Paclitaxel-Eluting Balloon and Stenting Versus Plain Balloon Plus Stenting Versus Directional Atherectomy for Femoral Artery Disease (ISAR-STATH). <i>Circulation</i> , 2017, 135, 2218-2226.	1.6	42
143	Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2011-2022.	2.8	109
144	Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	63

#	ARTICLE	IF	CITATIONS
145	Functional Characterization of the <i>GUCY1A3</i> Coronary Artery Disease Risk Locus. <i>Circulation</i> , 2017, 136, 476-489.	1.6	84
146	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 206-217.	1.4	39
147	Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2017, 244, 93-99.	1.7	40
148	Prognostic value of alkaline phosphatase in patients with acute coronary syndromes. <i>Clinical Biochemistry</i> , 2017, 50, 828-834.	1.9	11
149	Alkaline phosphatase and prognosis in patients with coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2017, 47, 378-387.	3.4	36
150	Predictors for long-term survival after transcatheter edge-to-edge mitral valve repair. <i>Journal of Interventional Cardiology</i> , 2017, 30, 226-233.	1.2	47
151	A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2017, 188, 53-64.	2.7	11
152	Gamma-glutamyl transferase and atrial fibrillation in patients with coronary artery disease. <i>Clinica Chimica Acta</i> , 2017, 465, 17-21.	1.1	11
153	Standardized Minimalistic Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using the SAPIEN 3 Device: Stepwise Description, Feasibility, and Safety from a Large Consecutive Single-Center Single-Operator Cohort. <i>Structural Heart</i> , 2017, 1, 169-178.	0.6	12
154	Multicenter Comparison of Novel Self-Expanding Versus Balloon-Expandable Transcatheter Heart Valves. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2078-2087.	2.9	84
155	Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Left Main Coronary Artery Stenosis. <i>JAMA Cardiology</i> , 2017, 2, 1079.	6.1	99
156	Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis. <i>Circulation</i> , 2017, 136, 1007-1021.	1.6	200
157	Association analyses based on false discovery rate implicate new loci for coronary artery disease. <i>Nature Genetics</i> , 2017, 49, 1385-1391.	21.4	571
158	Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2017, 390, 737-746.	13.7	160
159	Response to the letter to the editor: Mortality risk of elevated alkaline phosphatase in patients with coronary artery disease and percutaneous coronary intervention. <i>Clinical Biochemistry</i> , 2017, 50, 1328-1329.	1.9	0
160	Coronary balloon angioplasty, stents, and scaffolds. <i>Lancet, The</i> , 2017, 390, 781-792.	13.7	179
161	Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102,735 patients. <i>European Heart Journal</i> , 2017, 38, 3160-3172.	2.2	66
162	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	6.1	25

#	ARTICLE	IF	CITATIONS
163	Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents. JACC: Cardiovascular Interventions, 2017, 10, 1332-1340.	2.9	98
164	Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-MAIN and ISAR-MAIN 2 randomized clinical trials. Catheterization and Cardiovascular Interventions, 2017, 89, 1-10.	1.7	4
165	Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with ST-elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2017, 89, 367-374.	1.7	7
166	A pan-coronary artery angiographic study of the association between diabetes mellitus and progression or regression of coronary atherosclerosis. Heart and Vessels, 2017, 32, 376-384.	1.2	12
167	Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 2548-2556.	2.9	8
168	Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. Thrombosis and Haemostasis, 2017, 117, 1989-1999.	3.4	26
169	Bioresorbable vascular scaffolds for complex coronary anatomies: the carus flight for interventional cardiologists?. Cardiovascular Diagnosis and Therapy, 2017, 7, S98-S101.	1.7	0
170	State of the art: coronary artery stents “past, present and future. EuroIntervention, 2017, 13, 706-716.	3.2	63
171	Investigator-driven randomized trials. , 2017, , 272-282.		0
172	Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?. Journal of Thoracic Disease, 2016, 8, E417-E423.	1.4	6
173	Contemporary drug-eluting stents and companion polymers: durable is not synonymous with harm. Journal of Thoracic Disease, 2016, 8, E1413-E1415.	1.4	1
174	Prospective Evaluation of ¹⁸ F-Fluorodeoxyglucose Uptake in Postischemic Myocardium by Simultaneous Positron Emission Tomography/Magnetic Resonance Imaging as a Prognostic Marker of Functional Outcome. Circulation: Cardiovascular Imaging, 2016, 9, e004316.	2.6	107
175	A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial. American Heart Journal, 2016, 179, 69-76.	2.7	20
176	Fluoroscopic calcification-guided optimal deployment projection during transcatheter aortic valve replacement “The eye of the pigtail. (Follow the right cusp rule” Part II). Catheterization and Cardiovascular Interventions, 2016, 87, 996-998.	1.7	5
177	Optimal periprocedural antithrombotic therapy in percutaneous coronary intervention: Between a rock and a hard place?. Cardiovascular Revascularization Medicine, 2016, 17, 491-493.	0.8	0
178	Association of progression or regression of coronary artery atherosclerosis with long-term prognosis. American Heart Journal, 2016, 177, 9-16.	2.7	15
179	Prognostic value of gamma-glutamyl transferase in patients with diabetes mellitus and coronary artery disease. Clinical Biochemistry, 2016, 49, 1127-1132.	1.9	8
180	Prognostic Value of High-sensitivity Troponin T After Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. Revista Espanola De Cardiologia (English Ed), 2016, 69, 746-753.	0.6	4

#	ARTICLE	IF	CITATIONS
181	Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients. <i>Coronary Artery Disease</i> , 2016, 27, 385-390.	0.7	1
182	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 674-684.	2.9	51
183	Coding Variation in <i>ANGPTL4</i> , <i>LPL</i> and <i>SVEP1</i> and the Risk of Coronary Disease. <i>New England Journal of Medicine</i> , 2016, 374, 1134-1144.	27.0	427
184	Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. <i>Clinical Research in Cardiology</i> , 2016, 105, 575-584.	3.3	18
185	Drug-Coated Balloons for Revascularization of Infrapopliteal Arteries. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1072-1080.	2.9	29
186	Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial. <i>Cardiovascular Diabetology</i> , 2016, 15, 124.	6.8	13
187	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016, 182, 125-134.	2.7	108
188	Bifurcation intervention with a two-stent strategy: can one size fit all?. <i>European Heart Journal</i> , 2016, 37, 3406-3408.	2.2	4
189	Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1731-1742.	2.9	80
190	Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	3
191	High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2259-2268.	2.8	88
192	Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 906-915.	1.9	1
193	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1890-1901.	2.9	32
194	Polymer-free drug-eluting stents – a safe and effective option for ACS. <i>Nature Reviews Cardiology</i> , 2016, 13, 447-448.	13.7	2
195	Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis. <i>Scientific Reports</i> , 2016, 6, 33054.	3.3	14
196	Molecular multimodality imaging: has a long-standing dream come true?. <i>European Heart Journal</i> , 2016, 38, ehv768.	2.2	2
197	Drug-Eluting Balloons or Stents for Bare-Metal Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1256-1258.	2.9	3
198	Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. <i>Platelets</i> , 2016, 27, 796-804.	2.3	11

#	ARTICLE	IF	CITATIONS
199	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 28-38.	2.9	31
200	Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. European Heart Journal, 2016, 37, 1538.1-1549.	2.2	147
201	Gamma-glutamyl transferase and prognosis in patients with coronary artery disease. Clinica Chimica Acta, 2016, 452, 155-160.	1.1	19
202	Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet, The, 2016, 387, 537-544.	13.7	317
203	Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). American Journal of Cardiology, 2016, 117, 532-538.	1.6	17
204	Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 784-792.	2.9	52
205	Cardiogenic Shock. Journal of the American College of Cardiology, 2016, 67, 748-750.	2.8	4
206	Relation of Gamma-Glutamyl Transferase to Cardiovascular Events in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2016, 117, 1427-1432.	1.6	12
207	Predictors of Permanent Pacemaker Implantations and New-Onset Conduction Abnormalities With the SAPIEN 3 Balloon-Expandable Transcatheter Heart Valve. JACC: Cardiovascular Interventions, 2016, 9, 244-254.	2.9	149
208	Association of increased CD8 + and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting. Aids, 2016, 30, 1413-1421.	2.2	12
209	Bioresorbable Vascular Scaffold Technology Benefits From Healthy Skepticism. Journal of the American College of Cardiology, 2016, 67, 932-935.	2.8	12
210	Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). Thrombosis Research, 2016, 137, 72-78.	1.7	6
211	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e002995.	3.9	12
212	Pre-treatment with P2Y ₁₂ inhibitors in ACS patients: who, when, why, and which agent?. European Heart Journal, 2016, 37, 1284-1295.	2.2	52
213	High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease. Vasa - European Journal of Vascular Medicine, 2016, 45, 155-161.	1.4	14
214	Gamma-glutamyl transferase and cardiovascular disease. Annals of Translational Medicine, 2016, 4, 481-481.	1.7	85
215	Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial. EuroIntervention, 2016, 11, 1372-137.	3.2	60
216	Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. EuroIntervention, 2016, 11, e1275-e1282.	3.2	0

#	ARTICLE	IF	CITATIONS
217	Endovascular Therapy for Steno-Occlusive Subclavian and Innominate Artery Disease. <i>Circulation Journal</i> , 2015, 79, 537-543.	1.6	22
218	Procedure-related bleeding in elective percutaneous coronary interventions. <i>European Journal of Clinical Investigation</i> , 2015, 45, 263-273.	3.4	5
219	Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. <i>European Heart Journal</i> , 2015, 36, 2147-2159.	2.2	362
220	Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Balloon-Expandable Transcatheter Heart Valve. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1809-1816.	2.9	50
221	Overexpansion of the SAPIEN 3 Transcatheter Heart Valve. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 2041-2043.	2.9	61
222	Anatomic Guided Crossing of a Stenotic Aortic Valve Under Fluoroscopy: "Right Cusp Rule, Part III". <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 119-120.	2.9	11
223	Relation of Body Mass Index to Bleeding During Percutaneous Coronary Interventions. <i>American Journal of Cardiology</i> , 2015, 115, 434-440.	1.6	17
224	Bioresorbable Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 198-200.	2.9	21
225	Predictors of antiplatelet response to prasugrel during maintenance treatment. <i>Platelets</i> , 2015, 26, 53-58.	2.3	22
226	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , 2015, 36, 1252-1263.	2.2	366
227	Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. <i>European Heart Journal</i> , 2015, 36, 94-99.	2.2	98
228	Stratification of coronary artery disease patients for revascularization procedure based on estimating adverse effects. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 9.	3.0	3
229	Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2015, 36, 3202-3210.	2.2	75
230	Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 877-884.	2.9	85
231	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris) on Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 845-852.	1.6	32
232	Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. <i>European Heart Journal</i> , 2015, 36, 2608-2620.	2.2	187
233	The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry. <i>Thrombosis Research</i> , 2015, 136, 87-93.	1.7	27
234	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015, 36, 1762-1771.	2.2	297

#	ARTICLE	IF	CITATIONS
235	Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2015, 104, 887-901.	3.3	24
236	Optimal Imaging for Guiding TAVR: Transesophageal or Transthoracic Echocardiography, or Just Fluoroscopy?. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 361-370.	5.3	44
237	Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular Causes in Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 904-916.	2.8	91
238	Activated Clotting Time During Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	3.9	4
239	Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1619-1629.	2.8	401
240	Covered stents for endovascular repair of iatrogenic injuries of iliac and femoral arteries. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 156-162.	0.8	26
241	Prognostic value of thyroid-stimulating hormone within reference range in patients with coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1308-1315.	3.4	13
242	Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas GrÅ¼ntzig Lecture ESC 2014. <i>European Heart Journal</i> , 2015, 36, 3320-3331.	2.2	441
243	Prognosis after revascularization for left main coronary artery disease: insights from the crystal ball. <i>European Heart Journal</i> , 2015, 36, 1212-1215.	2.2	3
244	Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. <i>Lancet, The</i> , 2015, 386, 655-664.	13.7	261
245	Acute and Midterm Outcome After MitraClip Therapy in Patients With Severe Mitral Regurgitation and Left Ventricular Dysfunction. <i>American Journal of Cardiology</i> , 2015, 116, 749-756.	1.6	23
246	Duration of Dual Antiplatelet Therapy After Drug-eluting Stents Implantation: The Jury Is Still Out. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 827-829.	0.6	2
247	Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 35-42.	2.1	21
248	Antiplatelet Therapy Discontinuation and the Risk of Serious Cardiovascular Events after Coronary Stenting: Observations from the CREDO-Kyoto Registry Cohort-2. <i>PLoS ONE</i> , 2015, 10, e0124314.	2.5	12
249	Long-term outcomes of biodegradable versus durable polymer drug-eluting stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of individual patient data from three randomised trials. <i>EuroIntervention</i> , 2015, 10, 1425-1431.	3.2	20
250	Tools and Techniques - Clinical: Fluoroscopic balloon sizing of the aortic annulus before transcatheter aortic valve replacement (TAVR) â€“ follow the â€œright cusp ruleâ€“. <i>EuroIntervention</i> , 2015, 11, 840-842.	3.2	9
251	Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2015, 11, 196-203.	3.2	38
252	Proximal occlusion versus distal filter for cerebral protection during carotid stenting: updated meta-analysis of randomised and observational MRI studies. <i>EuroIntervention</i> , 2015, 11, 238-246.	3.2	20

#	ARTICLE	IF	CITATIONS
253	First use of an expandable sheath and transcaval access for transcatheter Edwards SAPIEN 3 aortic valve implantation. <i>EuroIntervention</i> , 2015, 11, 782-784.	3.2	11
254	Prognostic value of late gadolinium enhancement in cardiovascular magnetic resonance imaging after acute ST-elevation myocardial infarction in comparison with single-photon emission tomography using Tc99m-Sestamibi. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 216-225.	1.2	41
255	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 517-592.	1.4	2,164
256	Percutaneous edge-to-edge repair of the mitral valve in patients with degenerative versus functional mitral regurgitation. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 137-146.	1.7	40
257	Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. <i>American Heart Journal</i> , 2014, 168, 862-868.e1.	2.7	9
258	Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 182-189.	1.7	29
259	Bleeding complications in patients undergoing percutaneous coronary interventions. <i>Coronary Artery Disease</i> , 2014, 25, 247-257.	0.7	19
260	Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. <i>Coronary Artery Disease</i> , 2014, 25, 658-664.	0.7	5
261	Correlates of poor outcome among patients with bleeding after coronary interventions. <i>Coronary Artery Disease</i> , 2014, 25, 456-462.	0.7	6
262	Drug-eluting stents for drug-eluting stent restenosis. <i>Coronary Artery Disease</i> , 2014, 25, 633-635.	0.7	0
263	Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1981.	7.4	162
264	Safety and Efficacy of a Potential Treatment Algorithm by Using Manual Compression Repair and Ultrasound-Guided Thrombin Injection for the Management of Iatrogenic Femoral Artery Pseudoaneurysm in a Large Patient Cohort. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 207-215.	3.9	43
265	Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: Results from the ISAR-DESIRE 2 trial. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 69-75.	0.8	12
266	Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 131-136.	0.8	14
267	Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease. <i>Clinical Research in Cardiology</i> , 2014, 103, 49-56.	3.3	13
268	Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 495-504.	1.5	33
269	Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategyâ€”Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial. <i>Journal of Cardiovascular Translational Research</i> . 2014. 7. 91-100.	2.4	84
270	Impact of Coronary Anatomy and Stenting Technique on Long-Term Outcome After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 29-36.	2.9	44

#	ARTICLE	IF	CITATIONS
271	Current Treatment of In-Stent Restenosis. Journal of the American College of Cardiology, 2014, 63, 2659-2673.	2.8	443
272	Incidence and predictors of restenosis after coronary stenting in 10â€¦004 patients with surveillance angiography. Heart, 2014, 100, 153-159.	2.9	351
273	Comparison of Prasugrel and Bivalirudin vs Clopidogrel and Heparin in Patients With <scp>ST</scp>â€œSegment Elevation Myocardial Infarction: Design and Rationale of the Bavarian Reperfusion Alternatives Evaluation (<scp>BRAVE</scp>) 4 Trial. Clinical Cardiology, 2014, 37, 270-276.	1.8	17
274	Drug-coated balloon therapy in coronary and peripheral artery disease. Nature Reviews Cardiology, 2014, 11, 13-23.	13.7	180
275	Reproducibility of area at risk assessment in acute myocardial infarction by T1- and T2-mapping sequences in cardiac magnetic resonance imaging in comparison to Tc99m-sestamibi SPECT. International Journal of Cardiovascular Imaging, 2014, 30, 1357-1363.	1.5	31
276	ORAL iMMunosuppressive therapy to prevent in-Stent rEstenosis (RAMSES) cooperation: A patient-level meta-analysis of randomized trials. Atherosclerosis, 2014, 237, 410-417.	0.8	12
277	Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 64, 863-871.	2.8	88
278	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
279	Clinical outcomes of patients treated with Nobori biolimus-eluting stent: Meta-analysis of randomized trials. International Journal of Cardiology, 2014, 175, 484-491.	1.7	10
280	Pharmacological inhibition of coronary restenosis: systemic and local approaches. Expert Opinion on Pharmacotherapy, 2014, 15, 2155-2171.	1.8	23
281	Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study. International Journal of Cardiovascular Imaging, 2014, 30, 1087-1095.	1.5	17
282	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ, The, 2014, 348, g3859-g3859.	6.0	291
283	Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. European Heart Journal, 2014, 35, 2285-2294.	2.2	93
284	Drug-eluting stent trials: too much non-inferiority, too little progress?. Lancet, The, 2014, 383, 386-388.	13.7	12
285	Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients with Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. Thrombosis Research, 2014, 134, 558-564.	1.7	44
286	A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Thrombosis and Haemostasis, 2014, 112, 342-351.	3.4	41
287	Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Thrombosis and Haemostasis, 2014, 112, 1190-1197.	3.4	27
288	Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Thrombosis and Haemostasis, 2014, 111, 1041-1049.	3.4	16

#	ARTICLE	IF	CITATIONS
289	A prospective, non-randomized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis. American Journal of Cardiovascular Disease, 2014, 4, 87-99.	0.5	12
290	Comparative prognostic value of C-reactive protein & fibrinogen in patients with coronary artery disease. Indian Journal of Medical Research, 2014, 140, 392-400.	1.0	4
291	Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: Final results of the intracoronary stenting and angiographic restenosis test equivalence between two drug-eluting stents (ISAR-TEST) trial. Catheterization and Cardiovascular Interventions, 2013, 81, E23-8.	1.7	47
292	Standardized Imaging for Aortic Annular Sizing. JACC: Cardiovascular Imaging, 2013, 6, 249-262.	5.3	209
293	Unmet Aspirations "Where To Now for Catheter Thrombectomy?. New England Journal of Medicine, 2013, 369, 1649-1650.	27.0	8
294	Zotarolimus- Versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2013, 62, 2075-2082.	2.8	69
295	Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: A meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. International Journal of Cardiology, 2013, 168, 4002-4009.	1.7	40
296	Drug-Eluting Stents for Revascularization of Infrapopliteal Arteries. JACC: Cardiovascular Interventions, 2013, 6, 1284-1293.	2.9	95
297	C-reactive protein and prognosis in women and men with coronary artery disease after percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2013, 14, 264-269.	0.8	10
298	Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet, The, 2013, 381, 461-467.	13.7	347
299	Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction. American Heart Journal, 2013, 165, 537-543.	2.7	13
300	The Assessment of Area at Risk and Myocardial Salvage After Coronary Revascularization in Acute Myocardial Infarction. JACC: Cardiovascular Imaging, 2013, 6, 358-369.	5.3	37
301	Fluoroscopy-Guided Aortic Root Imaging for TAVR. JACC: Cardiovascular Imaging, 2013, 6, 274-275.	5.3	55
302	Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Second-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2013, 6, 1267-1274.	2.9	286
303	Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. American Heart Journal, 2013, 166, 534-540.	2.7	42
304	Chronic dysfunction of the endothelium is associated with mortality in acute coronary syndrome patients. Thrombosis Research, 2013, 131, 198-203.	1.7	15
305	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet, The, 2013, 382, 1879-1888.	13.7	127
306	Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. International Journal of Cardiology, 2013, 168, 5162-5166.	1.7	29

#	ARTICLE	IF	CITATIONS
307	Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography. Cardiovascular Revascularization Medicine, 2013, 14, 84-89.	0.8	20
308	Polymer-free Sirolimus-eluting Versus Polymer-based Paclitaxel-eluting Stents: An Individual Patient Data Analysis of Randomized Trials. Revista Espanola De Cardiologia (English Ed), 2013, 66, 435-442.	0.6	2
309	SORT OUT V: a new episode in the DES wars. Lancet, The, 2013, 381, 609-611.	13.7	4
310	Relation of Fibrinogen Level With Cardiovascular Events in Patients With Coronary Artery Disease. American Journal of Cardiology, 2013, 111, 804-810.	1.6	42
311	Stents liberadores de rapamicina sin pol�mero frente a stents liberadores de paclitaxel con pol�mero: un an�lisis de datos de pacientes procedentes de ensayos aleatorizados. Revista Espanola De Cardiologia, 2013, 66, 435-442.	1.2	11
312	Triple Therapy With Aspirin, Prasugrel, and Vitamin K Antagonists in Patients With Drug-Eluting Stent Implantation and an Indication for Oral Anticoagulation. Journal of the American College of Cardiology, 2013, 61, 2060-2066.	2.8	225
313	Two Rare Variants Explain Association with Acute Myocardial Infarction in an Extended Genomic Region Including the Apolipoprotein(A) Gene. Annals of Human Genetics, 2013, 77, 47-55.	0.8	10
314	Comparative efficacy of 2 zotarolimus-eluting stent generations: Resolute versus endeavor stents in patients with coronary artery disease. American Heart Journal, 2013, 165, 80-86.	2.7	33
315	Prognostic Value of Access and Non�Access Sites Bleeding After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 354-361.	3.9	53
316	Vascular access and closure in coronary angiography and percutaneous intervention. Nature Reviews Cardiology, 2013, 10, 27-40.	13.7	44
317	Intravenous �-Blockers in Primary Percutaneous Coronary Intervention. Circulation, 2013, 128, 1487-1489.	1.6	9
318	Tissue Characterization After Drug-Eluting Stent Implantation Using Optical Coherence Tomography. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1376-1383.	2.4	70
319	Individualization of dual antiplatelet therapy duration after drug-eluting stent implantation: paradigm and reality. European Heart Journal, 2013, 34, 872-874.	2.2	2
320	Collagen Plug Vascular Closure Devices and Reduced Risk of Bleeding with Bivalirudin Versus Heparin Plus Abciximab in Patients Undergoing Percutaneous Coronary Intervention for Non ST�segment Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2013, 26, 623-629.	1.2	4
321	Uric acid and prognosis in angiography�proven coronary artery disease. European Journal of Clinical Investigation, 2013, 43, 256-266.	3.4	40
322	Second�versus first�generation �elimus�eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISAR�TEST� trial. Catheterization and Cardiovascular Interventions, 2013, 82, E769-76.	1.7	13
323	A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel. Platelets, 2013, 24, 15-25.	2.3	7
324	Treatment of coronary drug-eluting stent restenosis: a journey back to the future?. Expert Review of Medical Devices, 2013, 10, 423-427.	2.8	0

#	ARTICLE	IF	CITATIONS
325	Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. <i>Thrombosis and Haemostasis</i> , 2013, 109, 517-254.	3.4	12
326	Pathway Analysis Using Genome-Wide Association Study Data for Coronary Restenosis – A Potential Role for the PARVB Gene. <i>PLoS ONE</i> , 2013, 8, e70676.	2.5	12
327	Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. <i>EuroIntervention</i> , 2013, 9, 797-802.	3.2	47
328	Statin pretreatment and presentation patterns in patients with coronary artery disease. <i>Cardiology Journal</i> , 2013, 20, 52-8.	1.2	12
329	No Association of <i>ABCB1</i> C3435T Genotype With Clopidogrel Response or Risk of Stent Thrombosis in Patients Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 82-88.	3.9	37
330	New-Generation Drug-Eluting Stents for Patients With Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 814.	7.4	6
331	Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 582-589.	3.9	117
332	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	2.2	5,034
333	Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 705-712.	3.9	29
334	No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 429-432.	1.5	12
335	Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2012, 125, 1424-1431.	1.6	207
336	Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. <i>European Heart Journal</i> , 2012, 33, 1214-1222.	2.2	359
337	Lost contact with vessel wall, signed contract with stent thrombosis?. <i>European Heart Journal</i> , 2012, 33, 1305-1308.	2.2	5
338	In the Bivalirudin Era, Are We Still Looking for a Potent Antiplatelet Agent?. <i>Current Vascular Pharmacology</i> , 2012, 10, 476-478.	1.7	1
339	Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. <i>Platelets</i> , 2012, 23, 395-398.	2.3	13
340	Duration of Dual Antiplatelet Therapy and Long-Term Clinical Outcome After Coronary Drug-Eluting Stent Implantation. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 381-391.	3.9	43
341	Intra-aortic balloon counterpulsation in patients with acute myocardial infarction without cardiogenic shock. A meta-analysis of randomized trials. <i>American Heart Journal</i> , 2012, 164, 58-65.e1.	2.7	23
342	Drug-eluting stents perform better than bare metal stents in small coronary vessels: A meta-analysis of randomised and observational clinical studies with mid-term follow up. <i>International Journal of Cardiology</i> , 2012, 161, 73-82.	1.7	25

#	ARTICLE	IF	CITATIONS
343	A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2159-2164.	2.8	569
344	Prognostic Value of a High On-Clopidogrel Treatment Platelet Reactivity in Bivalirudin Versus Abciximab Treated Non-“ST-Segment Elevation Myocardial Infarction Patients. <i>Journal of the American College of Cardiology</i> , 2012, 60, 369-377.	2.8	40
345	New anti-platelet agents: The end of resistance?. <i>Thrombosis Research</i> , 2012, 130, S53-S55.	1.7	7
346	Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2012, 33, 3078-3087.	2.2	115
347	Association of uric acid with mortality in patients with stable coronary artery disease. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 1780-1786.	3.4	55
348	Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. <i>Thrombosis and Haemostasis</i> , 2012, 107, 769-774.	3.4	10
349	Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2012, 101, 461-467.	3.3	46
350	Prognostic Value of Uric Acid in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2012, 109, 1260-1265.	1.6	72
351	Not all drug-eluting balloons are equally good for patients, not all patients are equally suitable for drug-eluting balloons. <i>EuroIntervention</i> , 2012, 8, 417-421.	3.2	7
352	ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. <i>Cardiology Journal</i> , 2012, 19, 61-69.	1.2	19
353	The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 999-1014.	1.5	4
354	No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. <i>European Heart Journal</i> , 2011, 32, 1605-1613.	2.2	174
355	Biodegradable Polymer Versus Permanent Polymer Drug-Eluting Stents and Everolimus- Versus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1325-1331.	2.8	131
356	Impact of the Everolimus-Eluting Stent on Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1569-1577.	2.8	258
357	Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation?ŽŽEditorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1129-1132.	2.9	15
358	Abciximab and Heparin versus Bivalirudin for Non-“ST-Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2011, 365, 1980-1989.	27.0	285
359	Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. <i>American Heart Journal</i> , 2011, 161, 68-75.	2.7	90
360	Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. <i>American Heart Journal</i> , 2011, 161, 605-610.	2.7	28

#	ARTICLE	IF	CITATIONS
361	Response from the authors to: The value of elevated high-sensitivity troponin T. American Heart Journal, 2011, 161, e35.	2.7	0
362	Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. American Heart Journal, 2011, 162, 518-526.e5.	2.7	48
363	A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. American Heart Journal, 2011, 162, 740-747.	2.7	24
364	Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. Clinica Chimica Acta, 2011, 412, 1350-1356.	1.1	16
365	Interleukin 18 gene variation and risk of acute myocardial infarction. Cytokine, 2011, 56, 786-791.	3.2	15
366	Variations of specific non-candidate genes and risk of myocardial infarction: A replication study. International Journal of Cardiology, 2011, 147, 38-41.	1.7	13
367	High platelet reactivity and clinical outcome – Fact and fiction. Thrombosis and Haemostasis, 2011, 106, 191-202.	3.4	63
368	Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction. Thrombosis Research, 2011, 127, 119-121.	1.7	16
369	The chromosome 9p21 region and myocardial infarction in a European population. Atherosclerosis, 2011, 217, 220-226.	0.8	23
370	Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet, The, 2011, 378, 1071-1078.	13.7	164
371	Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thrombosis and Haemostasis, 2011, 105, 107-112.	3.4	37
372	Extended evidence for association between the melanoma inhibitory activity 3 gene and myocardial infarction. Thrombosis and Haemostasis, 2011, 105, 670-675.	3.4	7
373	Ruptured versus stable plaques in human coronary arteries. Coronary Artery Disease, 2011, 22, 345-351.	0.7	3
374	Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina. European Journal of Clinical Investigation, 2011, 41, 1054-1062.	3.4	12
375	Effect of Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention. American Journal of Cardiology, 2011, 107, 871-878.	1.6	55
376	High-Sensitivity Troponin T Level and Angiographic Severity of Coronary Artery Disease. American Journal of Cardiology, 2011, 108, 639-643.	1.6	52
377	Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. European Heart Journal, 2011, 32, 32-40.	2.2	173
378	Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. Clinical Research in Cardiology, 2011, 100, 327-333.	3.3	16

#	ARTICLE	IF	CITATIONS
379	Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2011, 100, 561-570.	3.3	38
380	Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. <i>Clinical Research in Cardiology</i> , 2011, 100, 579-585.	3.3	4
381	Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. <i>Clinical Research in Cardiology</i> , 2011, 100, 691-699.	3.3	7
382	Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 494-501.	1.7	17
383	Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 161-166.	1.7	13
384	New Roads, New Ruts. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 165-167.	2.9	20
385	Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives. <i>Current Drug Targets</i> , 2011, 12, 1836-1847.	2.1	11
386	A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention. <i>Human Molecular Genetics</i> , 2011, 20, 4748-4757.	2.9	13
387	Everolimus-Eluting Versus Sirolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 371-377.	3.9	55
388	Polymer-Free Sirolimus- and Probucol-Eluting Versus New Generation Zotarolimus-Eluting Stents in Coronary Artery Disease. <i>Circulation</i> , 2011, 124, 624-632.	1.6	126
389	Is Diabetes the Achilles' Heel of Limus-Eluting Stents?. <i>Circulation</i> , 2011, 124, 869-872.	1.6	19
390	Prognostic Value of Coronary Computed Tomographic Angiography in Comparison With Calcium Scoring and Clinical Risk Scores. <i>Circulation: Cardiovascular Imaging</i> , 2011, 4, 16-23.	2.6	87
391	Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy. <i>European Heart Journal</i> , 2011, 32, 1121-1133.	2.2	84
392	Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 505-513.	3.9	16
393	CYP2C19 Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 514-521.	3.9	19
394	Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction. <i>EuroIntervention</i> , 2011, 7, 128-135.	3.2	8
395	Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 46-52.	1.0	27
396	ISAR - A Story of Trials With Impact on Practice -. <i>Circulation Journal</i> , 2010, 74, 1771-1778.	1.6	6

#	ARTICLE	IF	CITATIONS
397	Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. <i>Thrombosis and Haemostasis</i> , 2010, 104, 626-632.	3.4	28
398	Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. <i>Heart and Vessels</i> , 2010, 25, 27-34.	1.2	23
399	Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention. <i>Heart and Vessels</i> , 2010, 25, 294-298.	1.2	6
400	Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy. <i>Clinical Research in Cardiology</i> , 2010, 99, 13-19.	3.3	10
401	Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2010, 99, 345-357.	3.3	34
402	One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. <i>Clinical Research in Cardiology</i> , 2010, 99, 795-802.	3.3	22
403	Bleeding After Percutaneous Coronary Intervention With Bivalirudin or Unfractionated Heparin and One-Year Mortality. <i>American Journal of Cardiology</i> , 2010, 105, 163-167.	1.6	25
404	Peak Cardiac Troponin-T Level, Scintigraphic Myocardial Infarct Size and One-Year Prognosis in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2010, 106, 1212-1217.	1.6	53
405	Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 895-902.	1.7	13
406	Is diabetes a leveler of efficacy of DES types?. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 335-337.	1.7	1
407	Platelets contribute to postnatal occlusion of the ductus arteriosus. <i>Nature Medicine</i> , 2010, 16, 75-82.	30.7	158
408	Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2010, 103, 638-643.	3.4	5
409	4G/5G polymorphism and haplotypes of SERPINE1 in atherosclerotic diseases of coronary arteries. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1170-1180.	3.4	22
410	Erythropoietin in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 408-413.	3.9	122
411	Predictive Factors and Impact of No Reflow After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 27-33.	3.9	141
412	Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1821.	7.4	980
413	Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. <i>European Heart Journal</i> , 2010, 31, 582-587.	2.2	57
414	ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2010, 31, 2482-2491.	2.2	82

#	ARTICLE	IF	CITATIONS
415	Is it naive to load only clopidogrel-naïve patients prior to PCI?. European Heart Journal, 2010, 31, 1298-1300.	2.2	0
416	Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. European Heart Journal, 2010, 31, 1205-1211.	2.2	75
417	A Double-Blind, Randomized Study on Prevention and Existence of a Rebound Phenomenon of Platelets After Cessation of Clopidogrel Treatment. Journal of the American College of Cardiology, 2010, 55, 558-565.	2.8	55
418	5-Year Prognostic Value of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2010, 55, 2383-2389.	2.8	380
419	Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents. Journal of the American College of Cardiology, 2010, 55, 2710-2716.	2.8	192
420	2-Year Clinical and Angiographic Outcomes From a Randomized Trial of Polymer-Free Dual Drug-Eluting Stents Versus Polymer-Based Cypher and Endeavor, Drug-Eluting Stents. Journal of the American College of Cardiology, 2010, 55, 2536-2543.	2.8	108
421	Platelet Aggregation and Its Association With Stent Thrombosis and Bleeding in Clopidogrel-Treated Patients. Journal of the American College of Cardiology, 2010, 56, 317-318.	2.8	196
422	Myocardial Perfusion Grade, Myocardial Salvage Indices and Long-Term Mortality in Patients With Acute Myocardial Infarction and Full Restoration of Epicardial Blood Flow After Primary Percutaneous Coronary Intervention. Revista Espanola De Cardiologia (English Ed), 2010, 63, 770-778.	0.6	7
423	Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thrombosis and Haemostasis, 2010, 103, 151-159.	3.4	126
424	Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. American Heart Journal, 2010, 160, 355-361.	2.7	20
425	Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. American Heart Journal, 2010, 160, 506-512.	2.7	147
426	Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement. Circulation, 2010, 121, 512-518.	1.6	514
427	Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thrombosis and Haemostasis, 2010, 104, 1193-1200.	3.4	68
428	Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: Caseâ€“control study and a meta-analysis. Atherosclerosis, 2010, 208, 171-176.	0.8	27
429	Pharmacological prevention and management of restenosis. Expert Opinion on Pharmacotherapy, 2010, 11, 1855-1872.	1.8	4
430	Drug-Eluting Stent. , 2010, , 114-122.		0
431	A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol. EuroIntervention, 2010, 5, 976-980.	3.2	0
432	Primary Percutaneous Coronary Intervention. , 2010, , 65-77.		0

#	ARTICLE	IF	CITATIONS
433	Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2009, 101, 340-344.	3.4	23
434	Cangrelor â€” A Champion Lost in Translation?. <i>New England Journal of Medicine</i> , 2009, 361, 2382-2384.	27.0	24
435	Abciximab in Patients With Acute ST-Segmentâ€”Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading. <i>Circulation</i> , 2009, 119, 1933-1940.	1.6	300
436	Assessment of Platelet Function in Whole Blood by Multiple Electrode Aggregometry: Transport of Samples Using a Pneumatic Tube SystemThe Authorsâ€™ Reply. <i>American Journal of Clinical Pathology</i> , 2009, 132, 802-804.	0.7	12
437	Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. <i>European Heart Journal</i> , 2009, 30, 2714-2721.	2.2	224
438	Estimated Radiation Dose Associated With Cardiac CT Angiography. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 500.	7.4	891
439	Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. <i>European Heart Journal</i> , 2009, 30, 2441-2449.	2.2	207
440	Mechanical Reperfusion and Long-term Mortality in Patients With Acute Myocardial Infarction Presenting 12 to 48 Hours From Onset of Symptoms. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 487.	7.4	62
441	Prognostic Value of Kidney Function in Patients With ST-Elevation and Nonâ€”ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. <i>American Journal of Kidney Diseases</i> , 2009, 54, 830-839.	1.9	25
442	Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1142-1148.	2.9	20
443	Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 291-299.	2.9	156
444	No Association of Chromosome 9p21.3 Variation With Clinical and Angiographic Outcomes After Placement of Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1149-1155.	2.9	29
445	The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. <i>Biomaterials</i> , 2009, 30, 632-637.	11.4	57
446	Serum potassium levels on admission and infarct size in patients with acute myocardial infarction. <i>Clinica Chimica Acta</i> , 2009, 409, 46-51.	1.1	8
447	Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. <i>American Heart Journal</i> . 2009, 157, 620-624.e2.	2.7	91
448	Platelet Reactivity After Clopidogrel Treatment Assessed With Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis. <i>Journal of the American College of Cardiology</i> , 2009, 53, 849-856.	2.8	600
449	Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1760-1768.	2.8	180
450	The Only Better Alternative to Rescue Percutaneous Coronary Intervention Is Primary Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2009, 54, 127-129.	2.8	5

#	ARTICLE	IF	CITATIONS
451	Prognostic Value of Coronary Computed Tomographic Angiography for Prediction of Cardiac Events in Patients With Suspected Coronary Artery Disease. JACC: Cardiovascular Imaging, 2009, 2, 404-411.	5.3	238
452	Impact of Myocardial Salvage Assessed by 99mTc-Sestamibi Scintigraphy on Cardiac Autonomic Function in Patients Undergoing Mechanical Reperfusion Therapy for Acute Myocardial Infarction. JACC: Cardiovascular Imaging, 2009, 2, 449-457.	5.3	7
453	Drug-Eluting Stents Versus Bare-Metal Stents in Diabetic Patients With ST-Segment Elevation Acute Myocardial Infarction: A Pooled Analysis of Individual Patient Data From 7 Randomized Trials. Revista Espanola De Cardiologia (English Ed), 2009, 62, 354-364.	0.6	10
454	Drug-Eluting Stents in Percutaneous Coronary Intervention. Drug Safety, 2009, 32, 749-770.	3.2	63
455	Patterns of Presentation and Outcomes of Patients with Acute Coronary Syndromes. Cardiology, 2009, 113, 198-206.	1.4	36
456	Risk of combining PPIs with thienopyridines: fact or fiction?. Lancet, The, 2009, 374, 952-954.	13.7	37
457	Meeting report ESC Forum on Drug Eluting Stents, European Heart House, Nice, 27-28 September 2007. EuroIntervention, 2009, 4, 427-436.	3.2	4
458	Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. Thrombosis and Haemostasis, 2009, 101, 340-4.	3.4	5
459	Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thrombosis and Haemostasis, 2009, 101, 714-9.	3.4	91
460	Differential Healing Responses in Polymer- and Nonpolymer-Based Sirolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2008, 1, 535-544.	2.9	48
461	Estimate of myocardial salvage in late presentation acute myocardial infarction by comparing functional and perfusion abnormalities in predischage gated SPECT. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 906-911.	6.4	12
462	Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. Clinical Research in Cardiology, 2008, 97, 160-168.	3.3	12
463	Classification of coronary artery bifurcation lesions and treatments: Time for a consensus!. Catheterization and Cardiovascular Interventions, 2008, 71, 175-183.	1.7	260
464	Drug for a while, polymer for life: Is it a good solution?. Catheterization and Cardiovascular Interventions, 2008, 71, 340-341.	1.7	3
465	Is there a preferable DES in diabetic patients? A critical appraisal of the evidence. Catheterization and Cardiovascular Interventions, 2008, 72, 944-949.	1.7	8
466	Lack of support for association between common variation in TNFSF4 and myocardial infarction in a German population. Nature Genetics, 2008, 40, 1386-1387.	21.4	20
467	Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clinical Endocrinology, 2008, 68, 660-665.	2.4	78
468	Effect of Abciximab on Clinical and Angiographic Restenosis in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. American Journal of Cardiology, 2008, 101, 1226-1231.	1.6	5

#	ARTICLE	IF	CITATIONS
469	Treatment of Paclitaxel-Eluting Stent Restenosis With Sirolimus-Eluting Stent Implantation—Angiographic and Clinical Outcomes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 1134-1139.	0.6	3
470	Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions. <i>Journal of the American College of Cardiology</i> , 2008, 51, 690-697.	2.8	452
471	Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1429-1437.	2.8	136
472	Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2008, 52, 512-517.	2.8	69
473	A Meta-Analysis of 17 Randomized Trials of a Percutaneous Coronary Intervention-Based Strategy in Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2008, 52, 894-904.	2.8	175
474	A Randomized Clinical Trial to Evaluate the Safety and Efficacy of a Percutaneous Left Ventricular Assist Device Versus Intra-Aortic Balloon Pumping for Treatment of Cardiogenic Shock Caused by Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1584-1588.	2.8	904
475	Apolipoprotein E gene ϵ 2/ ϵ 3/ ϵ 4 polymorphism and myocardial infarction: Case-control study in a large population sample. <i>International Journal of Cardiology</i> , 2008, 125, 116-117.	1.7	9
476	Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials. <i>International Journal of Cardiology</i> , 2008, 126, 37-44.	1.7	121
477	Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. <i>American Heart Journal</i> , 2008, 155, 356-360.	2.7	46
478	Circulating homocysteine levels in patients with type 2 diabetes mellitus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 66-73.	2.6	48
479	Fibrinogen Genes and Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 758-763.	2.4	13
480	Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. <i>European Heart Journal</i> , 2008, 30, 916-922.	2.2	353
481	Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. <i>European Heart Journal</i> , 2008, 29, 1504-1509.	2.2	45
482	One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. <i>European Heart Journal</i> , 2008, 29, 455-461.	2.2	55
483	Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes. <i>European Heart Journal</i> , 2008, 29, 2868-2876.	2.2	92
484	Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. <i>European Heart Journal</i> , 2008, 30, 290-296.	2.2	51
485	Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. <i>European Heart Journal</i> , 2008, 29, 1975-1982.	2.2	182
486	Glycoprotein IIb/IIIa Receptor Inhibition with Abciximab during Percutaneous Coronary Interventions Increases the Risk of Bleeding in Patients with Impaired Renal Function. <i>Cardiology</i> , 2008, 111, 247-253.	1.4	10

#	ARTICLE	IF	CITATIONS
487	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. <i>BMJ: British Medical Journal</i> , 2008, 337, a1331-a1331.	2.3	270
488	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. <i>European Heart Journal</i> , 2008, 29, 2909-2945.	2.2	2,128
489	Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence. <i>Human Molecular Genetics</i> , 2008, 17, 1120-1126.	2.9	35
490	A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. <i>European Heart Journal</i> , 2008, 30, 923-931.	2.2	123
491	Are sirolimus-eluting stents superior to paclitaxel-eluting stents in patients with small-vessel disease?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 188-189.	3.3	1
492	Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. <i>New England Journal of Medicine</i> , 2008, 359, 688-696.	27.0	323
493	Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. <i>Thrombosis and Haemostasis</i> , 2008, 99, 121-126.	3.4	265
494	EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury. <i>Cardiovascular Research</i> , 2007, 77, 580-589.	3.8	13
495	Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. <i>European Heart Journal</i> , 2007, 28, 968-973.	2.2	35
496	Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. <i>European Heart Journal</i> , 2007, 28, 2706-2713.	2.2	337
497	Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. <i>European Heart Journal</i> , 2007, 28, 2720-2725.	2.2	26
498	Non-invasive coronary computed tomographic angiography for patients with suspected coronary artery disease: the Coronary Angiography by Computed Tomography with the Use of a Submillimeter resolution (CACTUS) trial. <i>European Heart Journal</i> , 2007, 28, 3034-3041.	2.2	129
499	Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. <i>European Heart Journal</i> , 2007, 28, 443-449.	2.2	222
500	A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. <i>European Heart Journal</i> , 2007, 28, 1814-1819.	2.2	198
501	Association of variants in the BAT1-NFKBIL1-LTA genomic region with protection against myocardial infarction in Europeans. <i>Human Molecular Genetics</i> , 2007, 16, 1821-1827.	2.9	23
502	Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. <i>New England Journal of Medicine</i> , 2007, 356, 1030-1039.	27.0	1,182
503	Lack of Benefit From Nitric Oxide Synthase Inhibition in Patients With Cardiogenic Shock. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1711.	7.4	7
504	No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. <i>Genetics in Medicine</i> , 2007, 9, 123-129.	2.4	28

#	ARTICLE	IF	CITATIONS
505	Platelet function in clopidogrel-treated patients with acute coronary syndrome. Blood Coagulation and Fibrinolysis, 2007, 18, 335-339.	1.0	39
506	New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective. Country Review Ukraine, 2007, 9, A4-A10.	0.8	1
507	Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: Results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. American Heart Journal, 2007, 154, 158.e1-158.e7.	2.7	21
508	Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. American Heart Journal, 2007, 154, 3-11.	2.7	103
509	Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. American Heart Journal, 2007, 154, 688-693.	2.7	91
510	Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, The, 2007, 370, 937-948.	13.7	1,329
511	Effectiveness of Drug-Eluting Stents in Patients With Bare-Metal In-Stent Restenosis. Journal of the American College of Cardiology, 2007, 49, 616-623.	2.8	149
512	Improved Noninvasive Assessment of Coronary Artery Bypass Grafts With 64-Slice Computed Tomographic Angiography in an Unselected Patient Population. Journal of the American College of Cardiology, 2007, 49, 946-950.	2.8	165
513	Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?. Journal of the American College of Cardiology, 2007, 49, 1265-1271.	2.8	34
514	Evolution of Left Ventricular Ejection Fraction and its Relationship to Infarct Size After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, 149-156.	2.8	100
515	A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 50, 1373-1380.	2.8	307
516	Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement. Catheterization and Cardiovascular Interventions, 2007, 70, 359-365.	1.7	36
517	Impact of Body Mass Index on Platelet Aggregation After Administration of a High Loading Dose of 600 mg of Clopidogrel Before Percutaneous Coronary Intervention. American Journal of Cardiology, 2007, 100, 203-205.	1.6	129
518	Accuracy of N-Terminal Pro-Brain Natriuretic Peptide to Predict Mortality in Various Subsets of Patients With Coronary Artery Disease. American Journal of Cardiology, 2007, 100, 575-578.	1.6	15
519	Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Thrombosis and Haemostasis, 2007, 97, 1003-12.	3.4	11
520	Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thrombosis and Haemostasis, 2007, 98, 852-7.	3.4	33
521	Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. European Heart Journal, 2006, 27, 260-266.	2.2	198
522	Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents. Journal of the American College of Cardiology, 2006, 47, 708-714.	2.8	172

#	ARTICLE	IF	CITATIONS
523	Cost Analysis From Two Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in High-Risk Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2006, 48, 262-267.	2.8	11
524	Prevalence of Noncalcified Coronary Plaques by 64-Slice Computed Tomography in Patients With an Intermediate Risk for Significant Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2006, 48, 312-318.	2.8	218
525	Vessel Size and Outcome After Coronary Drug-Eluting Stent Placement. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1304-1309.	2.8	87
526	Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms. <i>American Heart Journal</i> , 2006, 152, 1133-1139.	2.7	30
527	Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT® A double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. <i>American Heart Journal</i> , 2006, 151, 1248-1254.	2.7	14
528	A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. <i>Clinica Chimica Acta</i> , 2006, 373, 70-76.	1.1	10
529	Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. <i>Thrombosis and Haemostasis</i> , 2006, 95, 910-911.	3.4	93
530	Impact of P-glycoprotein on clopidogrel absorption. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 486-501.	4.7	361
531	N-Terminal Pro-Brain Natriuretic Peptide on Admission in Patients With Acute Myocardial Infarction and Correlation With Scintigraphic Infarct Size, Efficacy of Reperfusion, and Prognosis. <i>American Journal of Cardiology</i> , 2006, 97, 1151-1156.	1.6	29
532	Sustained increased risk of adverse cardiac events over 5 years after implantation of gold-coated coronary stents. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 690-695.	1.7	6
533	Association of Transforming Growth Factor- β 1 Gene Polymorphisms With Myocardial Infarction in Patients With Angiographically Proven Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1114-1119.	2.4	68
534	Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction. <i>European Heart Journal</i> , 2006, 27, 1900-1907.	2.2	54
535	Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. <i>European Heart Journal</i> , 2006, 27, 2524-2529.	2.2	63
536	Is there a role for oral rapamycin in restenosis prevention after bare-metal stent implantation?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 476-477.	3.3	0
537	Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor in Patients With Acute Myocardial Infarction & A Randomized Controlled Trial &. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1003.	7.4	394
538	Radiation Dose Estimates From Cardiac Multislice Computed Tomography in Daily Practice. <i>Circulation</i> , 2006, 113, 1305-1310.	1.6	657
539	Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment & The ISAR-REACT 2 Randomized Trial &. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1531.	7.4	682
540	Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss. <i>Circulation</i> , 2006, 113, 273-279.	1.6	176

#	ARTICLE	IF	CITATIONS
541	Age-Dependent Effect of Abciximab in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions. <i>Circulation</i> , 2006, 114, 2040-2046.	1.6	33
542	Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents. <i>Circulation</i> , 2006, 113, 2293-2300.	1.6	266
543	P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 199-204.	1.0	94
544	Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 511-515.	1.0	8
545	Critical role of bare-metal stent controls in trials of drug-eluting stents: reply. <i>European Heart Journal</i> , 2005, 26, 1687-1687.	2.2	0
546	Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. <i>American Journal of Cardiology</i> , 2005, 95, 553-557.	1.6	66
547	Comparison of C-Reactive Protein Levels Before and After Coronary Stenting and Restenosis Among Patients Treated With Sirolimus-Eluting Versus Bare Metal Stents. <i>American Journal of Cardiology</i> , 2005, 95, 1238-1240.	1.6	33
548	Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: A randomized double-blind controlled trial. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 374-380.	1.7	58
549	Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2005, 93, 35-39.	3.4	88
550	Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. <i>Cardiovascular Research</i> , 2005, 68, 483-492.	3.8	52
551	Genotyping of the Angiotensin I-Converting Enzyme Gene Insertion/Deletion Polymorphism by the TaqMan Method. <i>Clinical Chemistry</i> , 2005, 51, 1547-1549.	3.2	15
552	Distal Embolic Protection in Patients With Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1116.	7.4	14
553	Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 165-71.	7.4	534
554	Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting More Than 12 Hours From Symptom Onset<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2865.	7.4	238
555	No Replication of Association Between Estrogen Receptor $\hat{\pm}$ Gene Polymorphisms and Susceptibility to Myocardial Infarction in a Large Sample of Patients of European Descent. <i>Circulation</i> , 2005, 112, 2138-2142.	1.6	41
556	Paclitaxel-Eluting or Sirolimus-Eluting Stents to Prevent Restenosis in Diabetic Patients. <i>New England Journal of Medicine</i> , 2005, 353, 663-670.	27.0	462
557	Prevention of Restenosis by Systemic Drug Therapy. <i>Circulation</i> , 2005, 112, 2759-2761.	1.6	25
558	Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Patients With Chronic Stable Angina. <i>Circulation</i> , 2005, 112, 2102-2107.	1.6	67

#	ARTICLE	IF	CITATIONS
559	Sirolimus-Eluting Stents vs Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2005, 294, 819.	7.4	272
560	Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent Coating. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 748-753.	2.4	125
561	Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. European Heart Journal, 2005, 26, 1262-1268.	2.2	113
562	One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. European Heart Journal, 2005, 26, 1379-1384.	2.2	44
563	Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. European Heart Journal, 2005, 26, 1475-1481.	2.2	106
564	Randomized Comparison of a Titanium-Nitride-Oxide-Coated Stent With a Stainless Steel Stent for Coronary Revascularization. Circulation, 2005, 111, 2617-2622.	1.6	139
565	Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel. Circulation, 2005, 112, 2946-2950.	1.6	605
566	Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. Clinica Chimica Acta, 2005, 360, 178-186.	1.1	31
567	Iron status and clinical outcome in patients with coronary artery disease after coronary stenting. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 418-425.	2.6	5
568	Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. American Heart Journal, 2005, 150, 344-350.	2.7	54
569	Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. American Heart Journal, 2005, 150, 550-556.	2.7	17
570	Drug-eluting stents for diabetes mellitus. Journal of the American College of Cardiology, 2005, 45, 479-483.	2.8	45
571	Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction. Journal of the American College of Cardiology, 2005, 45, 828-831.	2.8	90
572	A Randomized, Double-Blind, Placebo-Controlled Trial on Restenosis Prevention by the Receptor Tyrosine Kinase Inhibitor Imatinib. Journal of the American College of Cardiology, 2005, 46, 1999-2003.	2.8	23
573	Late Restenosis in Patients Receiving a Polymer-Coated Sirolimus-Eluting Stent. Annals of Internal Medicine, 2005, 143, 392.	3.9	70
574	Evaluation of the Coroflex Theca-Stent for reduction of restenosis (ECORI). Journal of Invasive Cardiology, 2005, 17, 199-202.	0.4	5
575	A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thrombosis and Haemostasis, 2005, 93, 789-91.	3.4	3
576	Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction. Journal of Nuclear Medicine, 2005, 46, 1782-8.	5.0	22

#	ARTICLE	IF	CITATIONS
577	PLA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2004, 91, 141-145.	3.4	15
578	The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. <i>European Heart Journal</i> , 2004, 25, 335-341.	2.2	23
579	Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting. <i>European Heart Journal</i> , 2004, 25, 1635-1640.	2.2	19
580	A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel. <i>New England Journal of Medicine</i> , 2004, 350, 232-238.	27.0	557
581	Apolipoprotein E gene polymorphisms and thrombosis and restenosis after coronary artery stenting. <i>Journal of Lipid Research</i> , 2004, 45, 2221-2226.	4.2	12
582	Early Administration of Reteplase Plus Abciximab vs Abciximab Alone in Patients With Acute Myocardial Infarction Referred for Percutaneous Coronary Intervention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 947.	7.4	149
583	Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy. <i>Circulation</i> , 2004, 110, 1916-1919.	1.6	191
584	Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis. <i>Circulation</i> , 2004, 110, 790-795.	1.6	160
585	Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel. <i>Circulation</i> , 2004, 110, 3627-3635.	1.6	288
586	Local cyclinâ€dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drugâ€eluting stents to prevent neointima formation following vascular injury. <i>FASEB Journal</i> , 2004, 18, 1285-1287.	0.5	26
587	Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. <i>European Heart Journal</i> , 2004, 25, 1898-1902.	2.2	80
588	Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. <i>American Journal of Cardiology</i> , 2004, 93, 1201-1206.	1.6	53
589	Myocardial Salvage after Reduced-Dose Thrombolysis Combined with Glycoprotein IIb/IIIa Blockade Versus Thrombolysis Alone in Patients with Acute Myocardial Infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 17, 191-197.	2.1	3
590	Intracoronary stenting and angiographic results: Restenosis after direct stenting versus stenting with predilation in patients with symptomatic coronary artery disease (ISAR-DIRECT trial). <i>Catheterization and Cardiovascular Interventions</i> , 2004, 61, 190-195.	1.7	14
591	Drug-eluting stents for secondary prevention of restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 63, 265-266.	1.7	1
592	A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy. <i>Journal of the American College of Cardiology</i> , 2004, 43, 734-741.	2.8	57
593	Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2133-2136.	2.8	156
594	A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2073-2079.	2.8	55

#	ARTICLE	IF	CITATIONS
595	Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. <i>American Heart Journal</i> , 2004, 147, 457-462.	2.7	102
596	Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. <i>American Heart Journal</i> , 2004, 147, 317-322.	2.7	94
597	A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. <i>American Heart Journal</i> , 2004, 148, 105.	2.7	44
598	Sex-associated differences in clinical outcomes after coronary stenting in patients with diabetes mellitus. <i>American Journal of Medicine</i> , 2004, 117, 830-836.	1.5	8
599	Pharmacokinetics of clopidogrel after administration of a high loading dose. <i>Thrombosis and Haemostasis</i> , 2004, 92, 311-316.	3.4	215
600	Value of serum ferritin and soluble transferrin receptor for prediction of coronary artery disease and its clinical presentations. <i>Atherosclerosis</i> , 2004, 174, 105-110.	0.8	22
601	Tissue factor promotor polymorphism α^{603} A/G is associated with myocardial infarction. <i>Atherosclerosis</i> , 2004, 177, 189-191.	0.8	45
602	ABO locus O1 allele and risk of myocardial infarction. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 61-67.	1.0	31
603	Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction. <i>Journal of Nuclear Medicine</i> , 2004, 45, 725-9.	5.0	68
604	Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes. <i>American Journal of Kidney Diseases</i> , 2004, 44, 627-35.	1.9	15
605	Impact of acute myocardial infarct location on myocardial salvage after stenting or thrombolysis (results from the STOPAMI 1 and 2 trials): Stent versus Thrombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2003, 91, 341-343.	1.6	1
606	Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement. <i>Atherosclerosis</i> , 2003, 166, 171-176.	0.8	4
607	G protein beta 3 subunit 825T allele carriage and risk of coronary artery disease. <i>Atherosclerosis</i> , 2003, 167, 135-139.	0.8	28
608	Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. <i>Journal of the American College of Cardiology</i> , 2003, 41, 925-929.	2.8	58
609	Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STERO-2) trial. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1283-1288.	2.8	491
610	Angiotensin converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1957-1961.	2.8	20
611	4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. <i>American Heart Journal</i> , 2003, 146, 855-861.	2.7	19
612	Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STERO trial. <i>American Heart Journal</i> , 2003, 146, 882-886.	2.7	42

#	ARTICLE	IF	CITATIONS
613	Association between C-Reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. American Journal of Medicine, 2003, 114, 715-722.	1.5	88
614	Tumor necrosis factor- α , lymphotoxin- α , and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine, 2003, 24, 161-171.	3.2	49
615	Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment. European Heart Journal, 2003, 24, 1128-1133.	2.2	34
616	Evaluation of Prolonged Antithrombotic Pretreatment ("Cooling-Off" Strategy) Before Intervention in Patients With Unstable Coronary Syndromes. JAMA - Journal of the American Medical Association, 2003, 290, 1593-9.	7.4	402
617	Haptoglobin Genotype Is Predictive of Major Adverse Cardiac Events in the 1-Year Period After Percutaneous Transluminal Coronary Angioplasty in Individuals With Diabetes. Diabetes Care, 2003, 26, 2628-2631.	8.6	128
618	Leucine 7 to Proline 7 Polymorphism of the Preproenkephalin Y Gene is Not Associated with Restenosis after Coronary Stenting. Journal of Endovascular Therapy, 2003, 10, 566-572.	1.5	5
619	Homocysteine Status and Polymorphisms of Methylenetetrahydrofolate Reductase Are Not Associated With Restenosis After Stenting in Coronary Arteries. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 2229-2234.	2.4	23
620	Therapy-Dependent Influence of Time-to-Treatment Interval on Myocardial Salvage in Patients With Acute Myocardial Infarction Treated With Coronary Artery Stenting or Thrombolysis. Circulation, 2003, 108, 1084-1088.	1.6	138
621	Haptoglobin Gene Subtyping by Restriction Enzyme Analysis. Clinical Chemistry, 2003, 49, 1937-1940.	3.2	17
622	Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. European Heart Journal, 2003, 24, 820-827.	2.2	30
623	Gender and restenosis after coronary artery stenting. European Heart Journal, 2003, 24, 1523-1530.	2.2	105
624	Early Resolution of ST-Segment Elevation Correlates With Myocardial Salvage Assessed by Tc-99m Sestamibi Scintigraphy in Patients With Acute Myocardial Infarction After Mechanical or Thrombolytic Reperfusion Therapy. Circulation, 2002, 105, 2946-2949.	1.6	86
625	Sex-Based Analysis of Outcome in Patients With Acute Myocardial Infarction Treated Predominantly With Percutaneous Coronary Intervention. JAMA - Journal of the American Medical Association, 2002, 287, 210.	7.4	140
626	Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. American Journal of Medicine, 2002, 112, 13-18.	1.5	22
627	Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. Journal of the American College of Cardiology, 2002, 40, 882-889.	2.8	56
628	Statin treatment following coronary artery stenting and one-year survival. Journal of the American College of Cardiology, 2002, 40, 854-861.	2.8	51
629	Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet, The, 2002, 359, 920-925.	13.7	195
630	CD14 gene $\alpha^{*}159C/T$ polymorphism is not associated with coronary artery disease and myocardial infarction. American Heart Journal, 2002, 143, 971-976.	2.7	41

#	ARTICLE	IF	CITATIONS
631	Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small) Tj ETQq1 1 0.784314.6gBT /Overlock 107	1.7	46
632	Clopidogrel therapy in patients undergoing coronary stenting: Value of a high-loading-dose regimen. Catheterization and Cardiovascular Interventions, 2002, 55, 436-441.	1.7	46
633	Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clinical Chemistry, 2002, 48, 1377-82.	3.2	86
634	Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis, 2001, 159, 137-144.	0.8	175
635	Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. Journal of the American College of Cardiology, 2001, 37, 2066-2073.	2.8	42
636	Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2001, 357, 2085-2089.	13.7	122
637	Previous Cytomegalovirus Infection and Restenosis After Coronary Stent Placement. Circulation, 2001, 104, 1135-1139.	1.6	19
638	Restenosis in one lesion in patients with multilesion stenting occurs even when the companion lesion is free of restenosis. Catheterization and Cardiovascular Interventions, 2001, 53, 287-287.	1.7	2
639	A randomized trial comparing the hand-mounted JoStent with the premounted Multi-Link Duet stent in patients with coronary artery disease. Catheterization and Cardiovascular Interventions, 2001, 54, 414-419.	1.7	10
640	Restenosis after coronary placement of various stent types. American Journal of Cardiology, 2001, 87, 34-39.	1.6	272
641	Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. American Journal of Cardiology, 2001, 87, 397-400.	1.6	15
642	Usefulness of intracoronary brachytherapy for in-stent restenosis with a 188Re liquid-filled balloon. American Journal of Cardiology, 2001, 87, 463-466.	1.6	25
643	Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. American Journal of Cardiology, 2001, 88, 1120-1124.	1.6	22
644	Intracoronary Stenting and Angiographic Results. Circulation, 2001, 103, 2816-2821.	1.6	727
645	Influence of stent design on 1-year outcome after coronary stent placement: A randomized comparison of five stent types in 1,147 unselected patients. Catheterization and Cardiovascular Interventions, 2000, 50, 290-297.	1.7	121
646	Long-term outcome after coronary stenting. Current Controlled Trials in Cardiovascular Medicine, 2000, 1, 48.	1.5	33
647	Genetic risk factors and restenosis after percutaneous coronary interventions. Herz, 2000, 25, 34-46.	1.1	33
648	HPA-1 and HPA-3 Polymorphisms of the Platelet Fibrinogen Receptor and Coronary Artery Disease and Myocardial Infarction. Thrombosis and Haemostasis, 2000, 83, 559-562.	3.4	62

#	ARTICLE	IF	CITATIONS
649	Previous Cytomegalovirus Infection and Risk of Coronary Thrombotic Events After Stent Placement. <i>Circulation</i> , 2000, 101, 11-13.	1.6	31
650	A Randomized Trial Comparing Stenting With Balloon Angioplasty in Small Vessels in Patients With Symptomatic Coronary Artery Disease. <i>Circulation</i> , 2000, 102, 2593-2598.	1.6	168
651	Coronary Stenting plus Platelet Glycoprotein IIb/IIIa Blockade Compared with Tissue Plasminogen Activator in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2000, 343, 385-391.	27.0	428
652	Increased Risk of Restenosis After Placement of Gold-Coated Stents. <i>Circulation</i> , 2000, 101, 2478-2483.	1.6	186
653	Insertion/Deletion Polymorphism of the Angiotensin I-Converting Enzyme Gene Is Not Associated With Restenosis After Coronary Stent Placement. <i>Circulation</i> , 2000, 102, 197-202.	1.6	58
654	Primary intracoronary stenting in acute myocardial infarction: Long-term clinical and angiographic follow-up and risk factor analysis. <i>American Heart Journal</i> , 2000, 139, 208-216.	2.7	28
655	G Protein $\beta 2$ subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement. <i>Atherosclerosis</i> , 2000, 149, 151-155.	0.8	19
656	PIA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. <i>Journal of the American College of Cardiology</i> , 2000, 36, 84-89.	2.8	56
657	Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. <i>Journal of the American College of Cardiology</i> , 2000, 36, 2168-2173.	2.8	109
658	Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2000, 35, 915-921.	2.8	334
659	Primary intracoronary stenting in acute myocardial infarction: Long-term clinical and angiographic follow-up and risk factor analysis. <i>American Heart Journal</i> , 2000, 139, 0208-0216.	2.7	5
660	Influence of Balloon Pressure During Stent Placement in Native Coronary Arteries on Early and Late Angiographic and Clinical Outcome. <i>Circulation</i> , 1999, 100, 918-923.	1.6	69
661	Pl ^A Polymorphism of Platelet Glycoprotein IIIa and Risk of Restenosis After Coronary Stent Placement. <i>Circulation</i> , 1999, 99, 1005-1010.	1.6	153
662	Influence of lesion length on restenosis after coronary stent placement. <i>American Journal of Cardiology</i> , 1999, 83, 1617-1622.	1.6	194
663	Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. <i>American Journal of Cardiology</i> , 1999, 84, 987-991.	1.6	24
664	Clinical and angiographic follow-up after balloon angioplasty with provisional stenting for coronary in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 1999, 48, 151-156.	1.7	63
665	Prognostic Value of the Modified American College of Cardiology/American Heart Association Stenosis Morphology Classification for Long-Term Angiographic and Clinical Outcome After Coronary Stent Placement. <i>Circulation</i> , 1999, 100, 1285-1290.	1.6	116
666	Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1005-1012.	2.8	26

#	ARTICLE	IF	CITATIONS
667	Clinical and angiographic outcome after stent placement for chronic coronary occlusion. American Journal of Cardiology, 1998, 82, 803-806.	1.6	17
668	Operator volume and outcome of patients undergoing coronary stent placement. Journal of the American College of Cardiology, 1998, 32, 970-976.	2.8	73
669	Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. Journal of the American College of Cardiology, 1998, 32, 1866-1873.	2.8	444
670	Vessel Size and Long-Term Outcome After Coronary Stent Placement. Circulation, 1998, 98, 1875-1880.	1.6	433
671	Effect of Glycoprotein IIb/IIIa Receptor Blockade on Recovery of Coronary Flow and Left Ventricular Function After the Placement of Coronary-Artery Stents in Acute Myocardial Infarction. Circulation, 1998, 98, 2695-2701.	1.6	517
672	Intracoronary Stenting and Risk for Major Adverse Cardiac Events During the First Month. Circulation, 1998, 98, 104-111.	1.6	168
673	Interlesion Dependence of the Risk for Restenosis in Patients With Coronary Stent Placement in Multiple Lesions. Circulation, 1998, 97, 2396-2401.	1.6	83
674	Comparative in-vitro validation of eight first- and second-generation quantitative coronary angiography systems. Coronary Artery Disease, 1997, 8, 83-90.	0.7	45
675	Coronary Stent Placement in Patients With Acute Myocardial Infarction: Comparison of Clinical and Angiographic Outcome After Randomization to Antiplatelet or Anticoagulant Therapy. Journal of the American College of Cardiology, 1997, 29, 28-34.	2.8	128
676	Predictive Factors of Restenosis After Coronary Stent Placement. Journal of the American College of Cardiology, 1997, 30, 1428-1436.	2.8	612
677	Bimodal Distribution of Angiographic Measures of Restenosis Six Months After Coronary Stent Placement. Circulation, 1997, 96, 3880-3887.	1.6	47
678	A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery Stents. New England Journal of Medicine, 1996, 334, 1084-1089.	27.0	1,934
679	720-6 Stenting for Progressive Dissection During PTCA: Clinical, Angiographic and Intravascular Ultrasound Criteria to Define a Low-risk Group not Requiring Subsequent Anticoagulation. Journal of the American College of Cardiology, 1995, 25, 123A-124A.	2.8	6
680	Emergency coronary stenting for dissection during percutaneous transluminal coronary angioplasty: Angiographic follow-up after stenting and after repeat angioplasty of the stented segment. Journal of the American College of Cardiology, 1994, 23, 1053-1060.	2.8	71
681	Alanine aminotransferase as a marker of cardiovascular risk at high and low activity levels. Journal of Laboratory and Precision Medicine, 0, 4, 29-29.	1.1	18